Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Leukaemias
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Leukaemias
    TopAbstracts in Leukemias 07/01/2009 - (DGNews)
    TopAbstracts in Leukemias 06/24/2009 - (DGNews)
    Incidence of Febrile Neutropenia After Chemotherapy in Hospitalised Patients Appears Lower Than Expected in Canada: Presented at ICC - (DGDispatch)
    TopAbstracts in Leukemias 06/17/2009 - (DGNews)
    Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials - (JAMA)

    News archive

     Recent webcasts/CME - Leukaemias
    • Exploring New Trends in MDS & AML: From Clinical Data in Poor-Prognosis Patients to Mechanisms of Novel Agents
    • Interpreting New Findings on Epigenetic Changes in MDS and AML-What Impact Will They Have on Treatment?
    • Do Modified Treatment and Novel Therapies Augment Clinical Benefit in AML?
    • Crafting an Individualized Approach to MDS Therapy: New Data on Prognostic Models and Management of Higher Risk Disease
    • Bone Marrow Failure Syndromes Optimizing Outcomes Worldwide through Disease Understanding

      Webcasts/CME archive

       Recent cases - Leukaemias
        Chronic Neutrophilic Leukemia with Congenital Robertsonian Translocation Successfully Treated with Allogeneic Bone Marrow Transplantation in a Young Man
        Complete Remission of Primary Plasma Cell Leukemia with Bortezomib, Doxorubicin, and Dexamethasone: A Case Report
        An Unusual Presentation of Precursor T Cell Lymphoblastic Leukemia/Lymphoma with Cholestatic Jaundice: Case Report
        Gum Hypertrophy
        Cryptococcal Meningitis Presenting with Recurrent Syncope in a Patient with Chronic Lymphoid Leukemia: A Case Report

        Cases archive
          




        my personal edition > leukaemias > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Imatinib Alone Not a Long-Term Cure for Chronic Myeloid Leukemia: Presented at ASH

        By Mike Fillon

        ATLANTA, GA -- December 15, 2005 -- When discontinuation of imatinib therapy in patients with chronic myeloid leukemia (CML) inevitably results in a rapid loss of response, the cure is unlikely to be imatinib monotherapy, researchers said here at the 47th Annual Meeting of the American Society of Hematology (ASH).

        Previous studies concerning imatinib over the past 5 years have defined its role as an effective first-line therapy for CML patients with complete response (CP).

        However, Monica Bocchia, MD, associate professor, department of hematology, University of Siena, Siena, Italy, in a presentation on December 12th, noted that her research team also noted that when the drug was discontinued, so did the patients' recovery.

        In her study, her research team looked at the antitumor effect of a vaccine (CMLVAX100) targeting the BCR-ABL genes and found that it reduced any remaining tumor in some patients with CML who had reached a maximum response to imatinib.

        After a median time of 24 months of imatinib treatment, a group of 21 patients showing different degrees of persistent residual disease started vaccinations with CMLVAX100. Eight of the 21 patients presented with molecular disease, 10 had residual cytogenetic disease (range 2-45% of Ph+ metaphases), and 3 had only hematological response (100% of Ph+ metaphases).

        No improvement of their residual disease was documented for a median of 12 months (range 6-24) before starting initiating the vaccinations.

        Vaccine treatment plans included 6 vaccinations at 2-week intervals. In patients who responded to treatment, additional boosts of vaccine were provided every 4 to 6 months.

        To date, 18 of the 21 patients have completed the immunization regimen, 8 of whom received 4 additional boosts of vaccine.

        After six vaccinations, 6 patients with persisting, progressing disease reached a complete response, with 3 of them achieving an undetectable level of BCR-ABL transcript.

        In addition, 3 patients starting vaccinations with persistent molecular disease further reduced their BCR-ABL level, with 1 reaching molecular negativity. This suggests that CMLVAX100 works effectively with imatinib in CML-CP patients with persistent minimal residual disease.

        Of the 8 patients who underwent 4 additional boosts of vaccine, 1 reached a complete molecular response, 5 maintained the response obtained after immunization, and 2 patients (who previously achieved an undetectable level of BCR-ABL transcript) lost the complete molecular response (CMR), but maintained complete cytogenetic response.

        This finding suggests that while beneficial, a 6-month interval between boosts could be too long to maintain efficient immune control on residual leukemia cells, Dr. Bocchia noted.

        Although the number of patients who participated in the trial is small, this is a still an important study, she added.

        "Researchers have been attempting to develop cancer vaccines for decades, and results in CML patients are a very encouraging step forward," Dr. Bocchia concluded.


        [Presentation title: Control of Residual Disease in Imatinib Treated Chronic Myeloid Leukemia Patients With Peptide Vaccinations: 2 Years Follow up of CMLVAX100 Trial. Abstract 167]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send